Amgen Gets Mixed Ruling In Patent Fight

Law360, New York (August 3, 2006, 12:00 AM EDT) -- The U.S. Court of Appeals for the Federal Circuit Thursday issued a mixed ruling in Amgen Inc.’s nearly decade-long legal spat with two pharmaceutical companies over patents related to Amgen’s blockbuster anemia drug Epogen.

A recombinant version of the kidney hormone erythropoietin (EPO), Epogen is used to increase red blood cells in patients with kidney failure and in for patients on dialysis. Its sales were $613 million for the second quarter of 2006.

The case stretches back to April 1997, when Amgen sought declaratory judgment against...
To view the full article, register now.